YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in MCF-7 Cells via ERα and PI3K/Akt Pathways

Bingjie Xue1, Wei Huang1, Xia Yuan1, Bo Xu2, Yaxin Lou3, Quan Zhou1, Fuxiang Ran1, Zemei Ge4, Runtao Li4, and Jingrong Cui5,6

1. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 100083, Beijing, China; 2. Instrumental Analysis Center of State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 100083, Beijing, China; 3. Lab of Proteomics Medical and Healthy Analytical Center, Peking University, Beijing, China; 4. Peking University School of Pharmaceutical Sciences Department of Medicinal Chemistry, Beijing, China

Corresponding authors: Jingrong Cui, Email: jrcui@bjmu.edu; Runtao Li, Email: lirt@bjmu.edu.cn.

© 2015 Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.

Received: 2014.10.05; Accepted: 2014.11.15; Published: 2015.02.06

Abstract

Given that the proteasome is essential for multiple cellular processes by degrading diverse regulatory proteins, inhibition of the proteasome has emerged as an attractive target for anti-cancer therapy. YSY01A is a novel small molecule compound targeting the proteasome. The compound was found to suppress viability of MCF-7 cells and cause limited cell membrane damage as determined by sulforhodamine B assay (SRB) and CytoTox 96® non-radioactive cytotoxicity assay. High-content screening (HCS) further shows that YSY01A treatment induces cell cycle arrest on G2 phase within 24 hrs. Label-free quantitative proteomics (LFQP), which allows extensive comparison of cellular responses following YSY01A treatment, suggests that various regulatory proteins including cell cycle associated proteins and PI3K/Akt pathway may be affected. Furthermore, YSY01A increases p-CDC-2, p-FOXO3a, p53, p21Cip1 and p27Kip1 but decreases p-Akt, p-ERα as confirmed by Western blotting. Therefore, YSY01A represents a potential therapeutic for breast cancer MCF-7 by inducing G2 phase arrest via ERα and PI3K/Akt pathways.

Key words: YSY01A, PS341, MCF-7, High-content screening, Label-free quantitative proteomics, ERα, PI3K/Akt pathways

Introduction

The ubiquitin proteasome system (UPS) is crucial for the turnover of proteins by controlling cell cycle, programmed cell death, cell proliferation, survival, adhesion and differentiation. UPS dysregulation is implicated in the underlying molecular pathology of a variety of diseases, including cancer. Ubiquitin and various proteasome have thus become an attractive therapeutic target for treatment of malignancies. In the UPS, several ubiquitin ligases, such as RNF123, have been shown to bind directly to estrogen receptor-α (ERα) and regulate its activity. Besides, a number of studies have suggested that proteasome inhibition alters ERα-dependent gene transcription via diverse effects and mechanisms. For example, PS341 have been reported to inhibited ERα due to direct transcriptional inhibition and loss of RNA polymerase II recruitment on the ERα gene promoter. The ERα, expressed in over two thirds of breast cancers, plays an essential role on tumor growth, and blockade of the estrogen action is the mainstay of treatment of ER-positive breast cancer. However, activation of the phosphoinositide 3-kinase (PI3K) pathway occurs frequently in breast cancer. The over-activation of PI3K pathway promotes re-
sistance to the selective estrogen receptor modulators (SERMs) tamoxifen or aromatase inhibitor letrozole which are the first-line treatment for patients with ERα-positive breast cancer. The molecular mechanism reveals that ERα and the PI3K/Akt pathways form a positive feedback and their cross-talk has also been demonstrated in cancer cells. As the downstream target of PI3K/Akt signaling pathway, the kinase p70S6K can activate ERα by phosphorylation at Ser167 residue. Subsequently, activated ERα acts on PI3K, resulting in a positive feedback loop. Inhibition of PI3K pathway and ERα by proteasome inhibitors therefore represents a potentially attractive strategy for the treatment of breast cancer.

Proteasome inhibitor, as a new anticancer agent, is promising for anticancer therapy that benefit patients with multiple myeloma and non-hodgkin’s lymphoma. Bortezomib (also called PS341) have been approved for the treatment of multiple myeloma or relapsed/refractory mantle cell lymphoma. Bortezomib (also called PS341) have been demonstrated in cancer cells. As the downstream of PI3K/Akt signaling pathway, the kinase p70S6K can activate ERα by phosphorylation at Ser167 residue. Subsequently, activated ERα acts on PI3K, resulting in a positive feedback loop. Inhibition of PI3K pathway and ERα by proteasome inhibitors therefore represents a potentially attractive strategy for the treatment of breast cancer.

Herein, there is considerable interest in seeking a proteasome inhibitor, as a new anticancer agent, is promising for anticancer therapy that benefit patients with multiple myeloma and non-hodgkin’s lymphoma. Bortezomib (also called PS341) have been approved for the treatment of multiple myeloma or relapsed/refractory mantle cell lymphoma. These studies also reported that multiple myeloma cell lines that were previously resistant to melphalan, doxorubicin, dexamethasone, or mitoxantrone were sensitized up to 1,000,000-fold by prior exposure to sub-toxic concentrations of bortezomib are in clinical development because of their anti-neoplastic and anti-inflammatory effects. Bortezomib blocks TNF-α-induced NF-κB activation in a dose- and time-dependent manner in multiple myeloma cells through degradation of IκBα. Carfilzomib, the second generation proteasome inhibitor, is a more selective proteasome inhibitor with more mild toxicity compared to bortezomib and is also able to overcome resistance to chemotherapeutic agents. Besides, there are some proteasome inhibitors are under investigation, such as Marizomib (NPI-0052), Ixazomib (MLN9708), which are safety and efficacy in some patients from both phase I and II trials. However, their antitumor activity remains unsatisfactory, especially in most solid tumors such as breast cancer. Herein, there is considerable interest in seeking a proteasome inhibitor for the treatment of solid tumor malignancies.

Recently, our collaborator, Dr. RT Li, identified a novel proteasome inhibitor, YSY01A, we have demonstrated that YSY01A has less toxicity to livers, kidneys and intestines of nude mice and ICR mice compared with PS341 (data to be published). In this study, we further investigate inhibitory effect of YSY01A on tumor cell viability and find that the compound induces cell cycle arrest in MCF-7 cells. Together, we conclude that YSY01A promises a novel probe for development of proteasome inhibitors and a potential therapeutic for breast cancer treatment.

Materials and methods

Cell Culture

Human breast cancer cells MCF-7 were maintained as previously described. For all experiments, cells were cultured in RPMI-1640 medium (Macgene, China) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin (Macgene, China) in a 37°C humidified atmosphere containing 5% CO2 (Heraeus, Germany).

Cell Viability Assay

Cell viability and cytotoxicity of YSY01A to MCF-7 cells was determined using sulforhodamine B (SRB) colorimetric assay and CytoTox96® non-radioactive cytotoxicity assay. Briefly, 4,000 cells/well of MCF-7 cells were plated in a 96-well plate overnight. Cells were then treated with vehicle control (PBS), YSY01A (20, 40, 80 nM) or PS341 (40 nM) for 12, 24 and 48 hrs (SRB assay) or 24, 48 and 96 hrs (CytoTox96® assay), respectively. SRB assay was carried out as previously described. For CytoTox96 assay, cells were firstly lysed following the manufacturer’s instructions for determination of the maximum LDH release. On the other side, released LDH in culture medium of parallel groups was measured after brief spin down and harvest for detection of cell damage following treatments. The percentage of cellular injury was calculated using the formula: % cytotoxicity = experimental LDH released / maximum LDH release×100 and normalized to vehicle control.

Image Based Quantitative Analysis to Determine Cell Cycle Distribution by HCS

Click-iT® Alexa Fluor® 488 TUNEL imaging assay (Invitrogen, USA) was used to determine the effects of YSY01A on cell cycle. MCF-7 cells were seeded overnight in a 96 well imaging plate followed by treatment with 20, 40 and 80 nM YSY01A for 24 hrs, and then fixed with EdU (5-ethynyl-2'-deoxyuridine) for 1 hr and labeled with Alexa Fluor® 488 probe or labeled with antibody against phospho-histone 3 (p-H3). Cells were also co-stained with Hoechst 33342 dye to determine the DNA content based on the nuclear intensity and finally analyzed by high-content screening system equipped with Columbus analysis tool (Cellomics, USA). Cell cycle distribution was defined to S phase by incorporation of the thymidine analog, EdU, and M phase by immunostaining for the mitotic marker, p-H3, while the remaining unlabeled cells were identified to undergo G1 or G2 phases.

2D LC-MS/MS Label-free Quantitative Proteomic Analysis

2D LC-MS/MS label-free quantitative proteomic
analysis was used to investigate the molecular profiles of YSY01A in MCF-7 cells. To prepare cell culture samples, MCF-7 cells were exposed to vehicle control (PBS), YSY01A or PS341 for 24 hrs and lysed in ice-cold lysis buffer (8 M Urea, 75 mM NaCl, 50 mM Tris, protease inhibitor cocktail, pH 8.2) followed by sonication and high-speed centrifugation at 14,000 rpm for 30 mins. The resulting supernatants were harvested and their protein concentrations were measured using bicinchoninic acid protein assay (Dingguo Changsheng Biotechnology, China). Prior to proteomic analysis, protein samples were reduced by incubation with DTT at a final concentration of 5 mM for 25 mins at 56 °C and then alkylated by 14mM iodoacetamide for 30 mins in the dark. Unreacted iodoacetamide was quenched by adding 0.5 M DTT and incubated for 15 mins at room temperature in the dark, and the protein mixture was subsequently diluted 1:5 in 25 mM Tris-HCl, pH 8.2, to reduce the concentration of urea to 1.6M. CaCl₂ was added to a final concentration of 1 mM with addition of trypsin at 37 °C overnight. The digestion was stopped by acidification with 0.4% (vol/vol) trifluoroacetic acid followed by pH adjustment to 2.0 and centrifugation at 2,500g for 10 mins at room temperature. 200 µg of peptides from each sample were separated into 15 fractions by strong anion exchange as described previously. For 2D LC-MS/MS analysis, the eluted peptides were concentrated and purified and separated by reverse-phase chromatography (Xbridge™ C18 3.5um, 4.6x20mm column, and Xbridge™ BEH130 C18 3.5um,2.1x150mm column, Waters, Ireland). A nanoflow high performance liquid chromatography (HPLC) system (EASY-column,10 cm,ID 75um,3um, Thermo Fisher, USA) equipped was used to analysis, followed by redissolving in formic acid, and loading onto the column (EASY-column, 2 cm, ID 100um, 5um,C18, Thermo Fisher, USA). The 15 high-intensity peaks were used for MS/MS analysis using LTQ Orbitrap velos Pro. Finally, MaxQuant software version 1.4.1.2 was used for data analysis as previously described.

Western Blotting

The expression of proteins of interest was evaluated by Western blotting as we described previously. Whole cell lysates were extracted and separated on SDS-PAGE, followed by immunoblotting against antibodies. Immunoreactive bands were visualized using Bio-Rad system (Bio-Rad, USA) with enhanced chemiluminescence (Bio-Rad).

Statistical Analysis

Data are presented as the mean ±SD and analyzed by Student’s t-test for comparison of two groups, or by one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test for multiple comparison. Statistical significance was considered at *p<0.05, **p<0.01, ***p<0.001.

Results

YSY01A suppresses MCF-7 cells survival

To determine whether YSY01A suppresses the survival of human breast cancer cells MCF-7, the cell viability was assessed by SRB assay following treatment with 20, 40 and 80 nM YSY01A for 12, 24 and 48 hrs (Fig. 1A). The compound inhibited survival of MCF-7 cells in concentration- and time-dependent manners with significant difference observed at 24 and 48 hrs. Compared to vehicle control (PBS), 20, 40 and 80 nM YSY01A were found to reduce cell survival by 11.6%, 20.8% and 32.0% at 24 hrs as well as 26.8%, 44.2% and 66.4% at 48 hrs, respectively (p< 0.001 except for 11.6%). To further detect the cytotoxicity of YSY01A, LDH (lactate dehydrogenase) release, indicative of rupture of cell membranes following treatment, was measured in MCF-7 cells exposed to 20, 40 and 80 nM YSY01A for 24, 48 and 96 hrs. The results revealed that treatment with 80 nM YSY01A for 96 hrs raised LDH release by 69.7% and became 2.31 fold with statistical significance as compared with vehicle control (p< 0.01). At 24 and 48 hrs, although the LDH release increased in a concentration- and time-dependent manner, significant difference was not observed between YSY01A and vehicle control (Fig. 1B), suggesting that YSY01A inhibited the survival of MCF-7 cells with limited cell damage, so we speculate that cell cycle progression may be susceptible for YSY01A treatment.

YSY01A induces cell cycle arrest on G2 phase in MCF-7 cells

To investigate whether cell cycle arrest may contribute to loss of cell viability after YSY01A treatment, we further performed a cell cycle analysis using HCS. As shown in Fig. 2, increasing concentrations of YSY01A resulted in a dose-dependent rise in the relative NINI (normalized integrated nuclear intensity) value that corresponds to G2 phase. Exposure to YSY01A for 24 hrs caused an accumulation of cells on G2 phase from 28.6% (PBS) to 36.0% (40 nM) and 41.8% (80 nM) (Table 1). Taxol (Tax), which stabilizes microtubules by reducing their dynamicity and promotes mitotic arrest, was used as a positive control. Exposure to 100 nM Taxol caused M phase arrest in MCF-7 cells as determined by an increase in the NINI values. Thus, cell cycle arrest on G2 phase probably contributes to suppression of cancer cell survival in MCF-7 cells.
Figure 1. YSY01A inhibits survival of MCF-7 cells. MCF-7 cells were treated with either the vehicle (PBS), YSY01A 20, 40, 80 nM or PS341 40 nM for 12, 24 and 48 hrs (A) or 24, 48 and 96 hrs (B) followed by sulforhodamine B (SRB) assay (A) or CytoTox96® assay (B). Data are represented as the mean of three independent experiments performed in triplicate. ***p < 0.001

Figure 2. YSY01A induces cell cycle arrest in MCF-7 cells as determined by high-content imaging. Representative images of MCF-7 cells stained with EdU (5-ethynyl-2'-deoxyuridine)(a marker of S phase), p-H3 (a marker of M phase) and Hoechst 33342 (a marker of DNA), and the merge image also were shown. TAX represented the microtubules stabilizer taxol.

Table 1. Percentage induction cell cycle arrest in MCF-7

| Group  | Concentration (nM) | % Percentage of cell cycle distribution (mean±SD) | G1 | S  | G2 | M  |
|--------|-------------------|-------------------------------------------------|----|----|----|----|
| PBS    | 0                 | 26.8±4.7                                        | 43.3±3.8 | 28.6±1.9 | 1.5±0.6 |
| YSY01A | 20                | 17.2±1.3                                        | 53.9±1.8 | 28.3±0.8 | 0.5±0.2 |
|        | 40                | 34.1±1.6                                        | 21.6±3.9 | 36.0±4.5 | 1.7±0.8 |
|        | 80                | 18.6±0.2                                        | 38.8±1.2 | 41.8±1.4 | 0.8±0.0 |
| PS341  | 40                | 21.9±5.5                                        | 46.9±0.5 | 30.9±4.8 | 0.3±0.2 |
| TAX    | 100               | 22.9±3.9                                        | 32.4±4.3 | 28.9±5.1 | 15.6±6.2** |

YSY01A induces cell cycle arrest in MCF-7 cells as determined by high-content imaging. Cells were treated in triplicate at noted concentrations of YSY01A for 24 h. Distribution percentage of cell cycle phases based on NINI (normalized integrated nuclear intensity values) derived from the DNA binding dye (Hoechst 33342). NINI value is calculated by measuring the integrated nuclear intensity divided by the number of nuclei within each well. The NINI derived from mitotic nuclei (p-H3 labeled) were indicative of 4N DNA content, while NINI values for S phase (EdU labeled nuclei) were ranged between 0.5 and 1X NINI values of p-H3 (2N to 4N DNA content), and images were analyzed using Columbus software. *p < 0.05, **p < 0.01.

YSY01A affects PI3K pathway and cell cycle associated proteins

PI3K and cell cycle associated proteins were changed significantly by YSY01A in LFQP assay

To extensively explore molecular mechanisms of YSY01A, LFQP offers a robust means for obtaining proteome profiles of YSY01A (Fig. 3A). The results
showed that YSY01A was involved in regulation of apoptosis pathway, p53 associated pathway, mitochondrial dysfunction, endoplasmic reticulum stress, ubiquitin pathway, etc. PI3K pathway and cell cycle associated proteins were two of the most valuable and dominant fraction affected. The information of all proteins in the presence of 40 nM dose of YSY01A and PS341 were identified (Additional file 2: Supplemental data), and 395 peptides of 7560 whose abundances changed by more than two folds were identified (Fig. 3A&B). As shown in Fig. 3C, CDKN2A (p16), CDKN1A (p21Cip1) became 6.6 and 6.2 fold compared to vehicle control following exposure to YSY01A, while G2/M phase markers, CCNB1 (Cyclin B1) and CCNB2 (Cyclin B2), showed a 2.7 and 2.3 fold increase. Kinases in G2/M phase including CDC-6, CDC-20 and BUB1 exhibited a rise of 4.1, 2.6 and 2.3 fold, respectively, and YSY01A also increased levels of Wee1 to 2.2 fold. Sestrin 2 (SESN2), provides an important link between genotoxic stress, p53 and the mTOR signaling pathway, showed a 3.6 fold increase. And the profiles of PS341 were roughly coincident with YSY01A, apart from more intense enhancement in p16, p21Cip1 (6.9 and 8.8 fold change) and more mild increase in Wee1 (1.8 fold) compared with YSY01A. Moreover, quantitative analysis indicated that YSY01A may regulate PI3K pathway. For example, PIK3C3, Akt1 and PDK2 declined by 25.6%, 14.8%, 38.7% and p70S6K (RPS6KB1) decreased by 29.2%, whereas Deptor, an upstream inhibitor of mTORC1, was increased by 3.9 fold. The profiles of PS341 were also consistent with YSY01A except a slight increase in Deptor by 1.20 fold. These results were indicative of the potential involvement of YSY01A in regulation of cell cycle progression and PI3K pathway.

**YSY01A regulates expression of cell cycle, PI3K/Akt associated proteins and ERα**

To validate molecular profiles of YSY01A identified by LFQP, the G2/M phase marker, Cyclin B, CDC-2 and p-CDC-2 were firstly assessed by Western blotting. As shown in Fig. 4A, Cyclin B, CDC-2 and p-CDC-2 were all increased in MCF-7 cells treated with YSY01A, PS341 showed a similar trend as YSY01A with a slight increase in Cyclin B, and the similar results were obtained following YSY01A treatment at different time (Additional file 1: Fig. S1A). For the pivotal proteins involved in cell cycle transition, p53 were increased following YSY01A treatment, and the expression of p21Cip1 and p27Kip1 increased in the presence of 40 nM and 80 nM YSY01A (Fig. 4B). Moreover, it was not difficult to find that the bands began increasing at 3 hrs and reached a peak at 24 hrs (Additional file 1: Fig. S1B). However, the level of FoxO3a was decreased while its phosphorylation level was increased significantly. There was no obvious difference between PS341 and YSY01A, except PS341 treatment showed a more dramatic alternation in p53 and p27Kip1 than YSY01A. The increase of p21Cip1, p27Kip1 and p53 expression and activity caused by YSY01A suggested that the molecular change was significant for cell cycle arrest following YSY01A treatment.
Figure 4. YSY01A induces pivotal proteins involved in cell cycle transition and ERα in MCF-7 cells. After treatment of 20, 40, 80 nM YSY01A for 24 hrs or 40 nM PS341 for 24 hrs, expression of the cell cycle markers (A), cell cycle proteins (B) and ERα (C) were evaluated. Cell lysates were fractionated on SDS-polyacrylamide gels and analyzed by Western blotting with antibodies against cell cycle associated proteins. GAPDH was used as a loading control.

Figure 5. YSY01A modulates expression of PI3K pathway-related proteins. MCF-7 cells were treated with YSY01A at 20, 40, 80 nM for 24 hrs as directed and then subject for Western blotting analysis. L represented the positive control medicine rapamycin. GAPDH was used as a loading control.

Considering the potential role of YSY01A in regulation of PI3K pathway, the phosphorylation of Akt, an activator of mTOR, and its downstream effector p70S6K were also evaluated by Western blotting in MCF-7 cells following YSY01A treatment. As shown in Fig. 5A, 40 and 80 nM YSY01A significantly inhibited the phosphorylation of Akt (Ser473 and Thr308), and the inhibition appeared starting a treatment of 3 hrs (Additional file 1: Fig. S2A). Furthermore, Deptor, a depressor of mTOR, was definitely raised after exposure to 40 and 80 nM YSY01A for 24 hrs, and 40 nM PS341 induced the same outcome as well (Fig. 5B & S2C). Since Akt promotes cell cycle progression, we speculate that the decreased phosphorylation level of Akt may result in cell cycle arrest in MCF-7 cells treated with YSY01A or PS341.

Additionally, Western blotting revealed that ERα and p-ERα was down-regulated by YSY01A and PS341 (Fig. 4C & S1C). ERα is frequently overexpressed in the early stage of breast cancer and committed to modulate cell cycle progression, suggesting the response of ER-positive cells to YSY01A.

Discussion

The UPS plays a vital role in many cellular functions by selectively degrading key regulatory proteins. By blocking the action of proteasomes, proteasome inhibitors modulates cellular complexes that break down proteins and have been studied in anti-tumor treatment. Pre-clinical studies have revealed that bortezomib can sensitize the responses of cancer cells to chemotherapy agents and/or radiation therapy, for example 5-fluorouracil, cisplatin32, however, its toxicity prevents the achievement of higher drug concentrations and thus limits the efficacy of bortezomib monotherapy in certain cancers. Carfilzomib is a more selective proteasome inhibitor that is structurally distinct from bortezomib with reduced peripheral neuropathy. United States Food and Drug Administration granted authorization to carfilzomib in 2012.
for treatment of multiple myeloma\textsuperscript{33}. Pre-clinical data also support future clinical evaluation of carfilzomib in B-cell lymphoma\textsuperscript{34}. However, the present proteasome inhibitors are usually ineffective to most solid tumors, including breast cancer. The new proteasome inhibitor, YSY01A, represents our attempt to develop more potent and less toxic proteasome inhibitors, and available for more wide variety of tumors including solid tumor. Previous studies have demonstrated little toxicity of YSY01A in the tumor-bearing nude mice (data to be published). In this study, we found that YSY01A inhibits cell vitality and induces cell cycle arrest in human breast cancer cell line MCF-7, suggesting its potential use in antitumor therapy.

With the aid of LFQP, the molecular profiles of YSY01A was revealed as well. LFQP assay allows analysis of abundant data about the changes of proteins levels following YSY01A treatment via a robust and easy-to-implement label-free relative quantification approach. This technique also obviate the requirements of protein staining or peptide labeling\textsuperscript{35}. We identified a total of 7,561 non-redundant proteins from the 15 highest peaks in MS/MS, indicative of 52 categories changed, including the ubiquitination process, protein degradation (proteasome), mTOR, ErbB, cell cycle, and apoptosis. However, this assay could cause an omission of low-abundance proteins that may play an important role in cells’ life. In relative to the overall blueprint of intracellular proteins, Western blotting was used to validate the results of LFQP and make an excellent complement of the alteration of some low-level proteins.

Additionally, the combination therapy involving cyclophosphamide, doxorubicin, and 5-fluorouracil (5-FU) (CDF) is the most common chemotherapeutic regimen of breast cancer\textsuperscript{36}. Nevertheless, the clinical usefulness of CDF is limited by its remarkably low therapeutic window and frequent eruption of drug resistance. Therefore, development of chemo-preventive and therapeutic agents is needed to provide more therapeutic options, especially specific to drug resistance caused by PI3K/Akt over-expression. It has been demonstrated that blockade of the PI3K/Akt pathway can produce profound alterations in downstream gene expression\textsuperscript{37}, including p53, FoxO, p21, p27. It is worth to note that some reports are demonstrated that PS341 decreases drug resistance via altering DNA repair pathways\textsuperscript{38} and histone deacetylase\textsuperscript{39-40} in relapsed/refractory multiple myeloma. Moreover, a phase II study of the combination of endocrine treatment and bortezomib in patients revealed that resistance to anti-hormonal therapies may be the result of an activated NF-κB signalling pathway in breast cancer\textsuperscript{41}. NF-κB signalling pathway was not significantly altered after YSY01A and bortezomib treatment in our LFQP assay and the previous study of our group\textsuperscript{[data to be published]}. The main reason may be associated with the status of NF-κB, as NF-κB was enhanced when the cancer cells obtain the drug resistance\textsuperscript{42-43}, and the next plan in our group will focus on the effect of YSY01A on drug resistance when combined with other drugs.

ERα is another important therapeutic target in ERα-positive cancer cells, and a number of studies have reported the ERα alteration with bortezomib treatment. In addition to the previously mentioned studies,\textsuperscript{3-8} bortezomib has been also found to cause a strong increase in p21\textsuperscript{Cip1} mRNA level because of inhibit the ERα expression in ERα-positive cells\textsuperscript{44}. In our study, YSY01A significantly enhanced the expression of p21\textsuperscript{Cip1} and relatively slightly altered the status of ERα expression, although the activity of ERα (p-ERα) was significantly inhibited by YSY01A and PS341. For the reason, the positive feedback between ERα and p70S6K point to the potential cause, indeed, we observed that ERα and p70S6K activity were declined in MCF-7 cells following YSY01A and PS341 treatment.

In conclusion, our study reinforces the potential benefit of YSY01A in cancer treatment, and provides extensive description of the mechanism of YSY01A on cell cycle arrest. We suggest that YSY01A may inhibit cell cycle progression and up-regulate the tumor suppressor genes p53, p27\textsuperscript{Kip1} and p21\textsuperscript{Cip1} by inhibition of PI3K/Akt pathway and ERα activity in MCF-7 cells. Further studies directed at this strategy will provide more insights into the approach to interrupt proteasome for potential antineoplastic therapy.

**Supplementary Material**

Additional File 1: Figures S1-S2.
http://www.jcancer.org/v06p0319s1.pdf
Additional File 2: Supplemental data.
http://www.jcancer.org/v06p0319s2.xlsx

**Acknowledgments**

Funding for this project was provided by the Ministry of National Science and Technology National Major Scientific and Technological Special Project for “Significant New Drugs Development” Program (No. 2009 ZX0930010) and the State Key Program of National Natural Science Foundation of China (No. 81172915).

**Competing Interests**

The authors have declared that no competing interest exists.
References

1. D’Arcy P, Linder S. Molecular pathways: translational potential of deubiquitinasers as drug targets. Clin Cancer Res 2014; 20(15):3908-14.
2. Liu YI, Gao X, Deeb D, et al. Ubiquitin-proteasomal degradation of antiapoptotic survivin facilitates induction of apoptosis in prostate cancers cells by pristimerin. Int J Oncol 2014; 45(4):1731-41.
3. Johnsen SA, Gungor C, Prenzel T, et al. Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RBIM in breast cancer. J Clin Res 2009; 69(4):128-136.
4. Fan M, Nakshatri H, Nepew KP. Inhibiting protesomeal proteolysis sustains estrogen receptor-alpha activation. Mol Endocrinol 2004; 18(11):2603-15.
5. Londer DM, Nawaz Z, Smith CL, O’Malley BW. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 2000; 5:399-48.
6. Reid G, Hubner MR, Metivier R, et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha is required for responsive promoters in an integral feature of estrogen signaling. Mol Cell 2003; 11(3):695-707.
7. Powers GL, Ellison-Zebki SJ, Casa AJ, et al. Proteasome inhibition represses ERα gene expression in ER+ cells - a new link between proteasome activity and estrogen signaling in breast cancer. Oncogene 2010; 29(1): 1509-1518.
8. Zhang H, Sun L, Liang J, et al. The catalytic subunit of the proteasome is engaged in the entire process of estrogen receptor-regulated translation. EMBO J 2006; 25:4223-33.
9. Derou SS, Korach K. Estrogen receptors and human disease. J Clin Invest 2006; 116(3):561-70.
10. Ali S, Coombs RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2(5):101-12.
11. Josh Lauring, Ben Ho Park, Antonia C. Wolff. The Phosphoinositi-de-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer. J Natl Compr Canc Netw 2013; 11(6):670-707.
12. Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 2011; 13(2):R21.
13. Liu CY, Shiau CW, Kuo HY, et al. Cancerous SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur. J. Cancer 2006; 116(3):561-70.
14. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. The 26S proteasome is required for estrogen receptor-alpha transactivation. Mol Cell 2000; 5:399-48.
15. Zhang H, Sun L, Liang J, et al. The catalytic subunit of the proteasome is engaged in the entire process of estrogen receptor-regulated translation. EMBO J 2006; 25:4223-33.
16. Johnsen SA, Gungor C, Prenzel T, et al. Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RBIM in breast cancer. J Clin Res 2009; 69(4):128-136.
17. Derou SS, Korach K. Estrogen receptors and human disease. J Clin Invest 2006; 116(3):561-70.
18. Ali S, Coombs RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2(5):101-12.
19. Josh Lauring, Ben Ho Park, Antonia C. Wolff. The Phosphoinositi-de-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer. J Natl Compr Canc Netw 2013; 11(6):670-707.
20. Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 2011; 13(2):R21.
21. Liu CY, Shiau CW, Kuo HY, et al. Cancerous SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur. J. Cancer 2006; 116(3):561-70.
22. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. The 26S proteasome is required for estrogen receptor-alpha transactivation. Mol Cell 2000; 5:399-48.
23. Zhang H, Sun L, Liang J, et al. The catalytic subunit of the proteasome is engaged in the entire process of estrogen receptor-regulated translation. EMBO J 2006; 25:4223-33.
24. Johnsen SA, Gungor C, Prenzel T, et al. Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RBIM in breast cancer. J Clin Res 2009; 69(4):128-136.
25. Derou SS, Korach K. Estrogen receptors and human disease. J Clin Invest 2006; 116(3):561-70.
26. Ali S, Coombs RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2(5):101-12.
27. Josh Lauring, Ben Ho Park, Antonia C. Wolff. The Phosphoinositi-de-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer. J Natl Compr Canc Netw 2013; 11(6):670-707.
28. Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 2011; 13(2):R21.
29. Liu CY, Shiau CW, Kuo HY, et al. Cancerous SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur. J. Cancer 2006; 116(3):561-70.
30. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. The 26S proteasome is required for estrogen receptor-alpha transactivation. Mol Cell 2000; 5:399-48.
31. Zhang H, Sun L, Liang J, et al. The catalytic subunit of the proteasome is engaged in the entire process of estrogen receptor-regulated translation. EMBO J 2006; 25:4223-33.
32. Johnsen SA, Gungor C, Prenzel T, et al. Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RBIM in breast cancer. J Clin Res 2009; 69(4):128-136.
33. Derou SS, Korach K. Estrogen receptors and human disease. J Clin Invest 2006; 116(3):561-70.
34. Ali S, Coombs RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2(5):101-12.
35. Josh Lauring, Ben Ho Park, Antonia C. Wolff. The Phosphoinositi-de-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer. J Natl Compr Canc Netw 2013; 11(6):670-707.
36. Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 2011; 13(2):R21.
37. Liu CY, Shiau CW, Kuo HY, et al. Cancerous SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur. J. Cancer 2006; 116(3):561-70.
38. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. The 26S proteasome is required for estrogen receptor-alpha transactivation. Mol Cell 2000; 5:399-48.
39. Zhang H, Sun L, Liang J, et al. The catalytic subunit of the proteasome is engaged in the entire process of estrogen receptor-regulated translation. EMBO J 2006; 25:4223-33.
40. Johnsen SA, Gungor C, Prenzel T, et al. Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RBIM in breast cancer. J Clin Res 2009; 69(4):128-136.
41. Derou SS, Korach K. Estrogen receptors and human disease. J Clin Invest 2006; 116(3):561-70.
42. Ali S, Coombs RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2(5):101-12.
43. Josh Lauring, Ben Ho Park, Antonia C. Wolff. The Phosphoinositi-de-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer. J Natl Compr Canc Netw 2013; 11(6):670-707.
44. Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 2011; 13(2):R21.